April 14, 2022

Class Action Developments in the Circuit Courts

Subscribe to Our Newsletter

Newsletter


Ross Weiner

|

April 14, 2022

On January 7, 2022, we presented a one-hour PLI CLE titled  Trends in Consumer Product Class Actions and Strategies for Settling Them . Following that presentation, we decided to flesh out three Circuit Court class action decisions that illustrate the challenges that come with both prosecuting and defending class actions. What follows is an overview of: (i) the Briseno case, which simply cannot get over the finish line; (ii) the Renfro case, which helps explain puffery through dog food; and (iii) the George case, in which Starbucks had to defend its “best” coffee against claims that some of its Manhattan stores inappropriately use a certain type of “No-Pest Strip” to combat pest infestations. The three cases offer an interesting contrast. In the first, the parties want to resolve it, but for more than ten years have been unable to obtain the court’s blessing. In the latter two, the plaintiffs could not survive the pleading stage. Ah, the joys of class action litigation!

While nowadays consumer product litigation is focused on claims involving vanilla (see  here  and  here  and  here, among many others), whether a product is truly “non-toxic” (see  here  and  here), and what makes a product actually recyclable (see  here), in 2011, “natural” claims were all the rage. Included among those was a class action alleging that ConAgra’s product, Wesson Oil, was mislabeled as “100% natural” because it contained GMOs.  Briseno v. ConAgra Foods, Inc. , 2:11-cv-05379 (C.D. Cal.). The case’s progress has been measured in years, not months. In 2015, class certification was granted, with the 9th Circuit affirming two years later. 674 F. App’x 654 (9th Cir. 2017). The Supreme Court denied ConAgra’s petition for writ of certiorari. 138 S. Ct. 313 (2017). As you probably suspect, the story does not end there.

In 2017, ConAgra agreed to sell Wesson Oil to the J.M Smucker Company. About two months later, ConAgra, on its own volition, removed the “100% natural” label and stopped marketing Wesson products as “natural.” ConAgra has argued that the litigation played no role in its decisions. Then, in early 2018, the J.M. Smucker transaction fell through, and ConAgra decided to commence settlement negotiations in the  Briseno  case.

Beginning in June 2018, the parties, with the help of Magistrate Judge Douglas McCormick, started discussing settlement in earnest. Over the following six months, Magistrate Judge McCormick spent approximately 100 hours helping the parties narrow the issues. His approach was sound. First “he helped the parties determine how much ConAgra would agree to pay as relief to the class members.” Dkt. No. 779 at 5. Second, he “helped the parties determine how much Plaintiffs’ attorneys would recover in fees.”  Id. On the former, he helped the parties agree to a claims-made settlement that would pay class members $0.15/product for up to 30 units. While $0.15 might seem small, Magistrate Judge McCormick understood that it was “an amount considerably more than the price premium attributed to the ‘100% Natural’ label by Plaintiffs’ own expert.”  Id.  On the latter, even though plaintiffs’ counsels’ lodestar was more than $10 million, Magistrate Judge McCormick proposed—and the parties accepted—a fee request of $6.85 million, which ConAgra would not oppose (the “clear-sailing provision”). The parties agreed that if the court reduced the attorneys’ fee award, that money would revert to ConAgra (the “reverter clause”). Magistrate Judge McCormick also successfully proposed that the parties value the injunctive relief, i.e., the label change, at  $27 million . This would soon get very weird, however, because in December 2018, ConAgra agreed to sell the Wesson Brand to Richardson International. Accordingly, even if ConAgra had  wanted  to bring back the 100% natural label, it wouldn’t be able to, given that the brand was now owned by another entity. Not to worry: “After the sale, the parties revised the terms of the settlement agreement to clarify that the negotiated injunctive relief would apply to ConAgra  only if it reacquired the Wesson Brand .”  Id.  (emphasis added.).

On April 4, 2019, the district court preliminarily approved the settlement. Following the notice campaign, class members filed a total of 97,880 timely claims for approximately 2.8 million units worth a total maximum payout of $993,919. Six months later, the court granted final approval of the settlement, placing “great weight on the fact that the parties’ agreement had resulted from a court proposal from Magistrate Judge McCormick.”  Id.  Even though the sought-after attorneys’ fees were roughly seven times the amount the class received, the court approved them, noting that they constituted only half of counsels’ lodestar and reflected the “impressive result achieved given the weakness of Plaintiffs’ case.” In so doing, the court overruled an objector, class member Todd Henderson, who argued that the settlement—with the disproportionate amount of attorneys’ fees, clear-sailing provision, and reverter clause—was unfair and failed to satisfy F.R.C.P. 23(e).

In June 2021, the Ninth Circuit reversed the District Court’s approval order. It held that, even for post-class certification settlements (as this was), F.R.C.P. 23(e) imposes an independent obligation to “ensure that any class settlement is ‘fair, reasonable, and adequate,’” and this obligation includes a review of the attorneys’ fee award to ensure reasonableness. No. 19-56297 (June 1, 2021) at 31. Specifically, the Ninth Circuit found that lower courts must assess whether the  Bluetooth  red flags—i.e., (1) plaintiffs’ counsel receiving a disproportionate distribution of the settlement; (2) a clear-sailing provision; and (3) a reverter clause—are present, as they will help determine “if collusion may have led to class members being shortchanged.”  Id.  at 21. Because the ConAgra settlement “managed to run afoul of all three  Bluetooth  factors” and thus “favor[ed] class counsel and the defendant at the expense of the class members,” the Ninth Circuit remanded the case to the District Court to “give a hard look at the settlement agreement to ensure that the parties [had] not colluded at class members’ expense.”  Id.  at 24.

On remand, there were a few interesting developments.

First , Magistrate Judge McCormick submitted a declaration describing his role in the settlement negotiations. He offered two critical observations. On the one hand, he “saw nothing in the parties’ conduct before [him] to indicate that they were colluding at the class members’ expense.” Dkt. 739 ¶ 20. On the other hand, with respect to the “court proposals” he made to the parties, he conceded that they did not represent his evaluation of what is the “right outcome”; rather, they represented his “evaluation of the terms that [had] the best chance of being accepted by both sides.”  Id.  ¶ 14. Critically, he “did not at the time of the negotiations view [his] role as a settlement judge as reaching the issue of whether the settlement should be approved by the Court as fair, reasonable, and adequate.”  Id.  ¶ 19. This admission would become important later.

Second , the court largely agreed with the objector, Mr. Henderson, who reemerged to ask for discovery into the mediation process. The court allowed Mr. Henderson to obtain “discussions between Plaintiffs and Conagra” as well as “information or material shared with Judge McCormick.” Dkt. No. 750.

Third , in a renewed motion in support of final approval, plaintiffs, despite the Ninth Circuit’s discomfort with the case, asked the district court to grant final approval to the same exact settlement the Ninth Circuit had just remanded, arguing that despite the presence of all three  Bluetooth  red flags, the record confirmed that there was no “collusion” or “self-dealing.” Dkt. No. 783. This was not to be.

In December 2021, the district court denied plaintiffs’ motion for final approval of the settlement agreement. The court laid out this marker, noting that when all three  Bluetooth  red flags are present, that is a sign of “possible collusion” but  not  an automatic basis for settlement rejection. The district court opined, “When they are present, courts must scrutinize the settlement even closer to look for signs that self-interest, even if not purposeful collusion, has seeped its way into the settlement terms.” Dkt. 779 at 12.

Yet, at its core, the court’s conclusion is a bit of conundrum. The court conceded that the settlement was “not the product of collusion in the traditional sense,” i.e., “there is no evidence that class counsel and ConAgra intentionally schemed to enrich themselves at the expense of the class.” But setting that aside, the court focused on what appears to have been the real issue: the lack of proportionality between what the class and class counsel collected. The district court stated, “The fact that attorneys will receive nearly $7 million while the class receives less than $1 million is too disproportionate to ignore. This is particularly true when the structure of the settlement relied on compensating class members based on claims made, but the incentive for making such claims was extremely low.” But the incentive—or lack thereof—was the byproduct of a small-dollar product with an even smaller price premium. If you think about it, the entire situation is like a perfect storm for a settlement that seemingly cannot get over the finish line. But how did this come to be?

For starters, the litigation has been running for more than ten years, with class counsel seeking only 50% of its lodestar. So, class counsel’s fee request already represented a significant haircut over the costs incurred to date. And, as for the value of the claims at issue, the settlement provided the class with  more than it could have had it prevailed at trial . But ConAgra repeatedly made clear that it would not allow class members to reap a “windfall.” Dkt. No. 783 at 20. As a result, that the settlement contained a “reverter” clause is no surprise. To the extent the court reduced the attorneys’ fee award, if it went to the class, by definition the class would have reaped a windfall. The same issue would have infected a common fund settlement. Because the per product damages were so small, any sizable common fund settlement would have necessarily resulted in either (1) a windfall to the class; or (2) a large  cy pres  distribution (that likely would have attracted the same objectors, albeit utilizing a different objection). To make a long story short (or less long), the court’s decision calls into question how class counsel is supposed to resolve a long-running, time-consuming, and expensive class action over a low-dollar product without awarding the class more than it’s entitled to.

Like any good novel, the  ConAgra  case had an interesting epilogue. In early January 2022, plaintiffs moved the district court to reconsider the order denying final approval, arguing that the court’s denial of final approval was based solely on the amount of attorneys’ fees rather than the benefit to the class. In plaintiffs’ view, because the parties’ settlement agreement expressly granted the court discretion to reduce the attorneys’ fee award, they contend that the court should do just that “as part of approving the settlement.”

Unsurprisingly, the objector, Mr. Henderson, did not agree. Among other arguments, Mr. Henderson chided plaintiffs for failing previously to argue to the trial court that it could reduce the attorneys’ fee to a proportionate amount (whatever that may be), instead choosing “to play chicken with an all-or-nothing strategy.” Dkt. No. 791 at 1. And, as for what an appropriate fee would be—well—Mr. Henderson believed it should be zero.  Id.  at 9.

On the auspicious 2.22.22, the District Court had what will be, for now, the final word. In denying plaintiffs’ motion, the court clarified that it wasn’t  just  the disproportion between attorneys’ fees and class recovery that doomed the settlement. Rather, it was the disproportion

taken together  with other factors, including the clear sailing provision, the reverter provision, Judge McCormick’s explanation that he considered only what the parties would be likely to accept and not what was fair or just, the likely low claims rate, class counsel’s incentive to make sure claims did not get too high, and the worthless injunction—plus the evidence that the parties actually knew the claims rate would be extremely low and class counsel’s rejection of a more proportional settlement offer—[which] indicated that self-interest infected the negotiations.

Dkt. No. 795 at 7. So, it is back to the drawing board for the parties. Nearly eleven years into litigation and they are still no closer to resolving it.

In February 2022, the Tenth Circuit waded into territory that has bedeviled law students for ages: what is the line between misstatement and puffery? In  Renfro v. Champion Petfoods USA, Inc. , No 20-1274, a group of pet owners brought a class action against Champion Petfoods USA, Inc., alleging representations on its Acana and Orijen brands of dog food were false and misleading. Specifically, plaintiffs took issue with the following descriptors:

  • •“Trusted Everywhere”
  • •“Fresh and Regional Ingredients”
  • •“Ingredients We Love [From] People We Trust”
  • •“Biologically Appropriate”

Under Colorado law, to prevail on a claim brought under the Colorado Consumer Protection Act, a plaintiff must establish that the defendant made a “ false statement of fact  that either induces the recipient to act or has the capacity to deceive the recipient.”  Rhino Linings USA, Inc. v. Rocky Mt. Rhino Lining, Inc. , 62 P.3d 142, 144 (Colo. 2003) (emphasis added). On the other hand, “puffery” is used to “characterize those vague generalities that no reasonable person would rely on as assertions of particular facts.”  Alpine Bank v. Hubbell , 555 F.3d 1097, 1106 (10th Cir. 2009).

The district court dismissed the claims as either unactionable puffery or overly subjective and thus not materially misleading to a reasonable consumer. The Tenth Circuit affirmed, finding that the statements in question clearly landed on the puffery side of the ledger:

Table showing claims and the Tenth Circuit's reasoning for why they are not actionable.

In short, the common thread among the statements at issue is their inability to be measured. “Biologically appropriate” is basically a tautology: the product in question is dog food made for dogs. “Fresh and Regional Ingredients” are ingredients from somewhere (a region) that are largely fresh (and not old). And “Ingredients We Love from People We Trust” is incapable of “testing for falsifiability,” i.e., there is simply no way to know if someone at Champion neither loved some of the ingredients nor trusted the people who manufactured them. When a company’s statements are more general than specific, a 12(b)(6) motion to dismiss may succeed.

Over the past few years, Starbucks has seen its share of litigation, including cases involving: (1) a consumer  burning herself  after receiving the wrong coffee; (2) claims that vanilla Frappuccinos are made with  fake flavoring  instead of real vanilla; and (3) allegations that its lattes are  underfilled. In 2021, it fended off a different kind of case.

According to a few New York customers, Starbucks’ statements like “Best coffee for the Best You,” “Taste of Inspiration,” “Starbucks or nothing,” and “hear, soul, craft, pride, love[;] you won’t find that in any other cup of coffee” were all misleading because certain Manhattan locations utilized a “No-Pest Strip,” which is a time-release device that emits a powerful pesticide, 2,2-dichlorovinyl dimethyl phosphate (often abbreviated “DDVP”), into the air.  George v. Starbucks Corp. , 19-cv-6185 (motion to dismiss decided Nov. 19, 2020). The theory: because these devices are both designed for use only in unoccupied structures and can make you sick (although no plaintiffs complained that they got sick), that Starbucks used them rendered Starbucks’ glossy claims about its coffee and ambience false under New York’s consumer protection laws.

The district court dismissed in full the claims under New York General Business Law Sections 349 and 350, finding that the customers failed to “allege that Starbucks’s advertisements communicate—even indirectly—any specific details about its products.”  Id.  Further, the court noted that any claim that a seller’s “wares are ‘premium’ or ‘the best’ cannot support a cause of action for deceptive practices, whether made in a single advertisement or a hundred.”  Id.

For some reason, plaintiffs here decided to appeal to the Second Circuit, which had very little interest in resuscitating the claims.  George v. Starbucks Corp. , 20-4050 (decision Aug. 27, 2021). The Second Circuit affirmed the dismissal, holding that statements like “Best coffee for the Best You” and “Taste of Inspiration” are puffery, i.e., they “vaguely assert that Starbucks’s coffee is better than its competitors in a manner best ‘understood as an expression of the seller’s opinion only.’”  Id.  They “are not specific enough to ‘misrepresent an inherent quality or characteristic of the defendant’s product.’”  Id.

Moreover, the Second Circuit found that while certain statements “were plausibly specific enough to be more than puffery,” they refer “only to how Starbucks sources its products and crafts its coffee and the ingredients it uses in its baked goods.  No reasonable consumer would believe that these statements communicate anything about the use of pesticide in Starbucks’s stores .”  Id.  While the Second Circuit conceded that courts should “ ordinarily  refrain from resolving questions of reasonableness on a motion to dismiss,”  id. , every rule has an exception. And when the allegations at issue are so disconnected from the allegedly false claims, it simply is “not error” to dismiss those claims.  Id.

All in all, another win for Starbucks, and a glimmer of hope for other defendants looking to dispose of mislabeling claims at the pleading stage.

Ross Weiner   is the Legal Director at Risk Settlements, where he helps evaluate new business, assess legal and financial risk, and create optimal settlement designs and risk transfer options. Prior to joining Risk Settlements, Ross spent nine years as a litigator at Kirkland & Ellis LLP, where he focused on, among other things, class action disputes. During that time, Ross came to understand the importance of providing clients with creative approaches to settling disputes.

Ezra Church  counsels and defends companies in privacy, cybersecurity, and other consumer protection matters. He helps clients manage data security and other crisis incidents and represents them in high-profile privacy and other class actions. Focused particularly on retail, ecommerce, and other consumer-facing firms, his practice is at the forefront of issues such as biometrics, artificial intelligence, location tracking, ad tech, and blockchain. Ezra is a Certified Information Privacy Professional (CIPP) and co-chair of the firm’s Class Action Working Group.

This article originally appeared on https://plus.pli.edu/Details/Details?fq=id:(350194-ATL10).

Disclaimer: The viewpoints expressed by the authors are their own and do not necessarily reflect the opinions, viewpoints and official policies of Practising Law Institute.

This article is published on PLI PLUS, the online research database of PLI. The entirety of the PLI Press print collection is available on PLI PLUS—including PLI’s authoritative treatises, answer books, course handbooks and transcripts from our original and highly acclaimed CLE programs.

Certum Group Can Help

Get in touch to start discussing options.

Recent Content

By Certum Team June 25, 2026
Chambers & Partners, a leading independent legal research company, has once again recognized Certum Group and William Marra as leaders in the U.S. litigation finance industry. For the second consecutive year, Certum Group earned a Band 2 ranking in Chambers’ intellectual property litigation funding category, placing the firm among a small group of U.S. funders recognized as leaders in patent and IP finance. William Marra, a director at Certum Group, was again ranked individually, recognized in Band 3 for his work in litigation support. Reviewers interviewed by Chambers spoke to the depth and discipline of the Certum team: Certum has “some of the smartest people in the industry working there. I really respect them: they are efficient, they know the market, make smart decisions and are very discerning.” Certum’s team has “highly sophisticated legal and practical minds with an excellent grasp of litigation financing and the ebbs and flows of the litigation space.” “Certum Group are super credible, wonderful people. They are all real lawyers and they all care about our business.” One reviewer described Will as “bar none the most sophisticated, practical, partner-oriented funding professional I have worked with in my years of litigation funding involvement,” noting that he “has helped me shape cases in ways that dramatically improved their litigation and settlement posture” and is “adept and intuitively knowing of how to get to the right solutions.” Others described Will as “an excellent partner” and as someone who “bases decisions on fundamentals and has strong strategic vision.”  Click here to see the complete rankings.
By Certum Team June 17, 2026
Certum Group is pleased to announce that Suneal Bedi has joined the company as our Scholar in Residence. Suneal Bedi is an Associate Professor of Business Law & Ethics and Jerome Bess Faculty Fellow at the Kelley School of Business at Indiana University. He is also the Research Director at the Institute for Corporate Governance and Ethics. He teaches classes in corporate law and business ethics. Professor Bedi has written extensively on litigation finance and intellectual property in various outlets including Vanderbilt Law Review, USC Law Review, Harvard Journal of Law & Technology, Alabama Law Review, and has a forthcoming piece which empirically measures the value of litigation finance in the NYU Law Review. His work broadly seeks to analyze the marketplace effects of litigation finance with an emphasis on discussing the investment vehicle outside of the courtroom. Professor Bedi also brings an expertise in business ethics to the field and recently co-authored a textbook on the same titled The Vision of the Firm. He has assisted in many cases as an expert witness testifying on both IP damages and the business ethics of litigation finance. “It’s important that academic researchers spend time in the field learning how things actually work and I’m grateful for this opportunity,” Bedi said. He has a B.A. in Economics from Swarthmore College, a J.D. from Harvard Law School, an M.S. in Marketing and joint PhD in Business Ethics and Marketing from The Wharton School at the University of Pennsylvania. Before academia, he worked as a private equity associate at the Boston office of Ropes & Gray, LLP. See Suneal's announcement on Bloomberg Law , and learn more about his role at Certum Group HERE .
By W. Tyler Perry June 15, 2026
The CEO's Complaint In April 2026, Bayer CEO Bill Anderson stood before shareholders and made an argument that has become familiar in corporate boardrooms. Bayer had spent decades and billions developing products that undergo serious regulatory review. And yet, Anderson asked investors, why continue that work when it leaves the company “at the mercy of a 600-billion-dollar litigation industry”? The implication was clear. Litigation undermines the regulatory process. It second-guesses the scientists. It makes innovation irrational. Anderson was echoing an argument the defense bar has developed systematically for decades. John H. Beisner of Skadden Arps, in a series of reports for the Institute for Legal Reform , has argued that MDL proceedings pressure defendants to settle without examining the merits of individual claims. The Manhattan Institute’s James R. Copland has framed mass tort litigation as an economic drag on innovation . These positions represent the institutional consensus of the defense bar. And they rest on a factual premise that the evidentiary record contradicts. What the Record Shows Anderson was not speaking in the abstract. He was the CEO of the company that acquired Monsanto and inherited the Roundup litigation. That litigation has cost Bayer more than $11 billion in settlements and verdicts , with a further $7.25 billion proposed class settlement announced in February 2026 and granted preliminary court approval in March. Three days after Anderson’s remarks, Bayer’s attorneys stood before the United States Supreme Court in Monsanto Co. v. Durnell to argue that federal regulatory approval of glyphosate should preempt the state-law failure-to-warn claims that produced that liability. The company was not merely complaining about litigation. It was asking the Court to shut down the legal mechanism that had exposed what was in its own files. What was in the files is telling. In late 2025, the journal Regulatory Toxicology and Pharmacology retracted a twenty-five-year-old paper that had been cited for decades as evidence that glyphosate, the active ingredient in Roundup, was safe. The paper, Williams et al. (2000) , had concluded that glyphosate posed no carcinogenic risk to humans. Regulators relied on it. Defendants cited it in proceedings around the world. It shaped the scientific consensus for a generation. The retraction did not occur because new science emerged. It occurred because multidistrict litigation discovery exposed what peer review could not. The paper was ghostwritten . Internal Monsanto documents produced in the Roundup MDL (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Cal.) revealed that company scientists had drafted sections of the paper , managed the editorial process, and selected the nominally independent authors whose names appeared on it. A 2015 internal email from Monsanto scientist William Heydens discussed “how we handled Williams, Kroes and Munro,” referring to the company’s orchestration of the very research that regulators treated as independent science . The “rigorous approval process” Anderson invoked was built on a scientific record his company had manipulated. The regulatory system did not fail because litigation interfered with it. It failed because, without litigation, no one had the tools to discover the interference that was already there. The Pattern Monsanto is not the only company whose internal record told a different story than its public one. The pattern recurs across every successful mass tort of the past three decades. Litigation discovery exposes information that no other institution had the tools or incentive to uncover. Johnson & Johnson’s internal documents, produced through discovery in the talc cancer litigation, revealed that the company had known about asbestos contamination in its Baby Powder since the 1970s . Internal testing detected asbestos fibers . Strategic decisions followed about how to manage the information rather than the contamination. The UCSF Industry Documents Library has catalogued approximately 3,500 of these internal J&J documents. They had been inside J&J’s files for half a century. They emerged only because the litigation process compelled their production. In December 2025, a Baltimore jury returned a $1.5 billion verdict against J&J for a woman who developed mesothelioma after using its talc products, a case built on that same documentary record. It was the largest verdict ever awarded to an individual talc plaintiff. Then, in March 2026, The Lancet retracted a 1977 commentary that J&J had cited for decades to defend the safety of cosmetic talc because the author, Francis J.C. Roe, was an undisclosed paid J&J consultant who had shared drafts with the company and revised the paper based on its feedback. What is striking about these cases is not simply that the defendants knew more than they disclosed, or that regulators failed to detect the problem. It is that the system lacked the capacity to respond. The information gap was structural. Regulatory agencies lacked the subpoena power, the adversarial incentive, and in many cases the resources to obtain what litigation discovery produced. As I discussed in the third article in this series, Mass Torts as a Complement to, and Backstop for, Government Regulation , the systemic case for mass torts rests in part on the proposition that private enforcement supplements public regulation. The evidentiary record that MDL discovery produces is how that supplementation operates in practice. It is the foundation on which accountability depends. From Evidence to Accountability As any trial lawyer will tell you, producing documents is not the same as establishing legal facts. The MDL system includes two processes that convert raw discovery into usable evidence: Daubert proceedings and bellwether trials. Both serve filtering and calibrating functions that determine whether the information discovery produces can be translated into accountability. Daubert serves as a form of adversarial peer review. When general causation is contested, the MDL court evaluates the methodology underlying each side’s expert testimony with a rigor that the scientific peer review process itself often lacks. Daubert is no rubber stamp. The Lipitor MDL is the proof. More than 3,000 women alleged that the statin caused their type 2 diabetes, and the science looked plausible at the headline level. Large observational studies had associated statins with new-onset blood sugar changes, and the FDA had added language to the label. But the plaintiffs’ expert methodologies could not survive scrutiny. The district court excluded them, the Fourth Circuit affirmed in 2018 , and the litigation ended without a dollar changing hands. The pattern repeats. More than 300 Zoloft birth defect claims ended the same way in the Third Circuit . The Mirena MDL ended after a 156-page opinion excluding all seven plaintiff experts, affirmed by the Second Circuit . The Onglyza heart failure MDL ended in the Sixth Circuit in 2024 . Four mass torts, four courts of appeals, zero settlements. The system worked precisely as designed. It filtered claims that could not meet the evidentiary threshold, and the appellate courts confirmed it got the answers right. Anderson’s “600-billion-dollar litigation industry” framing implies an indiscriminate machine. The record demonstrates precisely the opposite. Bellwether trials serve a different function. They calibrate. By trying a representative set of cases to verdict, bellwether trials generate the data that makes rational settlement possible. In the 3M military earplugs MDL , sixteen bellwether trials produced ten plaintiff verdicts and six defense verdicts. That distribution informed the eventual $6 billion settlement. The settlement matrix that allocated recovery across nearly 260,000 claims was built on trial data that differentiated by injury type, severity, and evidentiary strength. The verdicts ran in both directions because the system was measuring, not rubber-stamping. That data could not have been generated any other way. When I evaluate a potential mass tort investment, the first questions are specific. Is general causation supported by methodologies that will survive a Daubert challenge, or does it rely on extrapolations that a well-resourced defense will dismantle? Has the discovery produced internal documents showing the defendant knew, and if so, how specific are they? Is there a bellwether track record, and what does the verdict spread tell you about how juries process the evidence? The quality of the evidentiary record is what separates a case I will fund from a case I will not. That record depends on the discovery apparatus the MDL (and its state-court equivalents) provides. The distinction matters to funders. It should matter to everyone who cares about the quality of outcomes the system produces. What Changed Knowledge Produces Return to Anderson’s complaint. The Bayer CEO framed litigation as a threat to innovation, a system that punishes companies for bringing products to market despite regulatory approval. The framing is powerful because it is partly true. No rational company wants to face billions of dollars in liability after spending billions on development. But the framing collapses when you ask a prior question: what was the quality of the regulatory record that approved the product in the first place? In Roundup’s case, the regulatory record was contaminated by the very company now asking the Supreme Court to immunize it from the consequences. The MDL did not undermine the approval process. It exposed the fact that the approval process had already been undermined, from the inside, by the regulated entity itself. That is not a system run amok. It is a system doing what it was built to do. The Roundup retraction. The EPA PFAS limits. The FDA opioid warnings. The $1.5 billion talc verdict built on documents J&J kept from the public for fifty years . These are the observable consequences of a system that forces information into the open. Information that powerful institutions had every incentive to suppress and that no other mechanism was positioned to extract. I freely admit that the system has real costs and that there are legitimate critiques, which the next article, The Case Against Mass Torts (And What It Gets Right), will address directly. But those costs must be weighed against what the system produces. What it produces is not just verdicts and settlements. It is a changed informational landscape, one in which regulators have better data, markets have better signals, scientific literature is more honest, and the public has access to facts that were previously locked inside corporate filing cabinets. None of this is free. The depositions that produced the Monsanto emails and the J&J memos cost real money. So did the experts, the document review, the years of pretrial proceedings. That investment comes from plaintiffs, their counsel, and increasingly from litigation funders who look at an evidentiary record and make a bet that the truth, once forced into the open, will produce accountability. It is not charity, nor is it pure altruism. But the track record strongly suggests the system is socially beneficial, uncovering corporate wrongdoing that has a concrete effect on people’s lives. And the structure that makes it possible is worth defending. Particularly from those with the most to lose when the record comes to light. That is the proposition that anchors this series. Private enforcement is not an accident of American institutional design. It is how the system was built to work. The MDL’s information function, the adversarial discovery process, and the capital that funds it are the mechanism through which private actors supplement public regulation in practice. Whether that mechanism survives the current moment is the question the remaining articles will take up. Preemption challenges are before the Supreme Court. Tort reform is advancing in state legislatures. Litigation funding is under political attack. ——— W. Tyler Perry is the Director of Mass Tort Strategy at Certum Group, a litigation finance advisory firm. He writes about the institutional architecture of the American civil justice system. The views expressed here are his own.